 Shares of Relmada Therapeutics Inc. RLMD, -0.97 fell 80.0 in premarket trading on Thursday after the biotech said its experimental treatment for major depressive disorder as a monotherapy did not meet the primary endpoint in a Phase 3 clinical trial. The company said it is still enrolling patients in two other late-stage studies assessing the therapy as an adjunctive treatment. 